Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.54 |
| ▸ | HTR2A | P28223 | 11/20 | 0.54 |
| ▸ | HTR2B | P41595 | 9/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468100 | 0.84 | HTR2C (0.56) | HTR2CHTR2AHTR2B | |
| SCHEMBL6468095 | 0.84 | HTR2C (0.56) | HTR2CHTR2AHTR2B | |
| SCHEMBL6464056 | 0.80 | DYRK1A (0.36) | HTR2CHTR2AHTR2BDRD3 | |
| SCHEMBL6464066 | 0.80 | DYRK1A (0.36) | HTR2CHTR2AHTR2BDRD3 | |
| SCHEMBL6431435 | 0.74 | BCL2A1 (0.46) | DRD3 | |
| SCHEMBL6431436 | 0.74 | BCL2A1 (0.46) | DRD3 | |
| SCHEMBL6411291 | 0.71 | HTR2C (0.76) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL6431421 | 0.71 | BCL2A1 (0.44) | DRD3 | |
| SCHEMBL6431417 | 0.71 | BCL2A1 (0.44) | DRD3 | |
| SCHEMBL6466632 | 0.71 | HTR2A (0.40) | HTR2CHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-6924289-B2 | Benzyl(Idene)-lactam derivatives, their preparation and their use as selective (ANT) agonists of 5-HT1A- and/or 5-HT1D receptors | PFIZER INC (US) | 2005-08-02 | — | — | US | disclosed |
| US-20030027812-A1 | Benzyl(idene)-lactam derivatives, their preperation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462048-B2 | 3-(2-(4-METHYLPIPERAZIN-1-YL)-BENZYLIDENE)-1,3-DIHYDRO-INDOL-2-ONE FOR EXAMPLE; USEFUL AS PSYCHOTHERAPEUTIC AGENTS | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020028821-A1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | HOWARD HARRY R (US) | 2002-03-07 | — | — | US | disclosed |
| EP-0894085-A1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | PFIZER INC. (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1997036867-A1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028821-A1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | HTR1E, HTR1D, HTR1A | HTR2C 7/4885HTR2A 14/4885HTR2B 12/4885 |
| US-20030027812-A1 | Benzyl(idene)-lactam derivatives, their preperation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors | HTR1A, HTR1E, HTR1D | HTR2C 11/4885HTR2A 10/4885HTR2B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.